The micro view of your reputation

Alzheimer’s in the Media: How Has the Latest Progress Changed Pharma Comms?

For a long time, the media debate around Alzheimer’s has been dominated by news of failed clinical trials – giants such as Merck, Eli Lilly and Pfizer, as well as lesser-known companies like Axovant and Prana Biotech, have all announced defeats in the last several years. As a consequence, pharma players haven’t developed a particular PR and communications playbook relating to one of medicine’s biggest challenges, and their messaging has been reduced to merely announcing disappointing results.

Alzheimer’s: Influencer Network Analysis (INA) Report

The report analyses the most recent media debate around Alzheimer’s. We used Influencer Network Analysis (INA), Commetric’s proprietary methodology, to identify the key spokespeople driving the discussion around the disease, and to rank the companies in terms of their influence on the discussion.

Commetric sourced and qualitatively analysed 683 English-language articles published between 1 January-10 October 2021 in a set of pre-defined global publications. These comprised top mass media outlets like Reuters, the New York Times, Forbes and the Guardian, as well as leading industry publications such as British Medical Journal, Fierce Healthcare and Kaiser Health News.

Mental Health: How Can Healthcare Companies Join the Wider Debate?

The COVID-19 pandemic has exacerbated preexisting mental health challenges, giving a stronger impetus to the debate around depression and anxiety in both healthcare and mass media.

Our media analysis found that the conversation in health industry outlets was mainly press release-driven, meaning healthcare companies primarily relied on owned and paid media.